Combination chemotherapy with methyl-CCNU, 5-fluorouracil, and vincristine in adenocarcinoma and large cell carcinoma of the lung
Bernath, A.M.; Cohen, M.H.; Ihde, D.C.; Fossieck, B.E.; Matthews, M.J.; Minna, J.D.
Cancer Treatment Reports 60(9): 1393-1394
1976
ISSN/ISBN: 0361-5960 PMID: 189924 Document Number: 104305
The regimen was quite tolerable with respect to hematologic and other toxic effects. The most frequent reason for dosage reduction was thrombocytopenia (50% of the patients had platelet count nadirs .ltoreq. 100,000 platelets/mm3). All of the 19 patients were considered evaluable for response. Although no patient in the study experienced a complete or partial response, 2 (both with adenocarcinoma) had minor responses with transient shrinkage of nodes and stabilization of chest disease for 8 and 20 wk, respectively. Eight additional patients had stable disease for periods ranging from 8-13 wk. Six of the 8 patients with stable disease had adenocarcinoma and 2 had large cell carcinoma. Of the 15 patients who had progressive disease, 9 had progression of chest disease alone, 4 had simultaneous progression in the chest and other metastatic sites, and 2 had progression in remote metastases alone. With 7 of the 19 patients still alive, the median survival time for the group was 15.0 wk from the 1st day of treatment (by life-table analysis). The median time to progression was 11.0 wk. This combination-drug treatment has insufficient activity to warrant further study in these lung cancer cell types.